Halozyme Therapeutics Inc: Corporate and Strategic Assessment Report - Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company Profile

Published Date: June 2008 Published By: Datamonitor Page Count: 44 Order Code: R313-34257 $495.00   Online Download $990.00   Global Site License   Questions About This Report E-mail a Colleague Printable Page Fax Your Order Description Table of Contents Search Inside this Report Similar Products Overview Catalyst Summary Company Structure Company Overview and Key Facts Business Description History Company Financials Stock Market Performance P&L Balance Sheet Cash Flow Products & Services Marketed Products Pipeline Products Historical Product Sales AC Forecast Product Sales Competitors and Strategic Business Relationships Key Competitors Key Suppliers Key Clients Shareholding Structure Strategy Company View Corporate Strategy SWOT Analysis Overview Strengths Weaknesses Opportunities Threats Value Chain Analysis Overview Product Development Scorecard Overview Scorecard Analysis Key Employees List of Key Employees Key Employee Biographies Financial and Operational Overview Financial and Operational Overview APPENDIX Ask the analyst Datamonitor consulting Disclaimer TABLE OF FIGURES Figure 1: Halozyme Therapeutics - Key Strategic Revenues, 2002-2006 ($ Mn) Figure 2: Halozyme Therapeutics - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn) Figure 3: Halozyme Therapeutics - Key Strategic Revenues, 2006-2010 ($ Mn) TABLE OF TABLES Table 1: Halozyme Therapeutics - Key Facts Table 2: Halozyme Therapeutics - Year-End Share Price and Market Capitalization, 2002-2006 ($) Table 3: Halozyme Therapeutics - Key Events Impacting Share Price Performance Table 4: Halozyme Therapeutics - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn) Table 5: Halozyme Therapeutics - Operating Cost Ratio Analysis, 2002-2006 (% of total revenues) Table 6: Halozyme Therapeutics - Balance Sheet Table 7: Halozyme Therapeutics - Cash Flow Table 8: Halozyme Therapeutics - Marketed Products Table 9: Halozyme Therapeutics - In-house Pipeline Products Table 10: Halozyme Therapeutics - Revenue Breakdown by Division, 2002-2006 ($ Mn) Table 11: Halozyme Therapeutics - Forecast Sales, 2006-2010 ($ Mn) Table 12: Halozyme Therapeutics - Key Competitors Table 13: Halozyme Therapeutics - Key Suppliers Table 14: Halozyme Therapeutics - Key Clients Table 15: Halozyme Therapeutics - Key Shareholders Table 16: Halozyme Therapeutics - SWOT Analysis Summary Table 17: Halozyme Therapeutics - Value Chain Analysis Table 18: Halozyme Therapeutics - Scorecard Table 19: Halozyme Therapeutics - Key Employees Table 20: Halozyme Therapeutics- Financial and Operational Overview Similar Products • Biophotonics: A Strategic Assessment of Photonics Technologies for Biomedical Applications, 2nd Edition Published Dec 2008 by Kalorama Information • Biotechnology Report Published Nov 2008 by Wall Street Transcript • MarketWatch: Biotechnology Published Nov 2008 by Datamonitor • Amgen Inc. - SWOT Analysis - SWOT Analysis Published Nov 2008 by Datamonitor • The Royalty Rate Report 2009: A Comprehensive Assessment of Valuation in the Pharmaceutical Sector Published Nov 2008 by PharmaVentures Ltd. • 13th Annual International Detection Technologies 2008 Conference Documentation Published Nov 2008 by Knowledge Foundation • Freedonia Focus on Biochip Products & Services Published Nov 2008 by Freedonia Focus • Effective Competitive Intelligence: A "How-To" Guide for Life Science Companies Published Nov 2008 by Kalorama Information • Biodetection Technologies 5th Edition Published Nov 2008 by Knowledge Foundation • Biotechnology in the US - Industry Risk Rating Report Published Oct 2008 by IBISWorld